Evidence map›Paper›PMID 40634107›Full record

ArticleLife science alliance2025

Loss of PLA2G4E compromises synaptic structure and cognitive outcomes in mice.

Sara Badesso, Marta Perez-Gonzalez, Sara Exposito, Maria Espelosin, Clara Cambria, Laura D'Andrea, Gabriele Imperato, Pedram Moeini, Africa Vales, Gloria Gonzalez-Aseguinolaza and 6 more

Abstract read
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sara BadessoGene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, Pamplona, Spain.
Marta Perez-GonzalezGene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, Pamplona, Spain.ORCID 0000-0002-1693-3361
Sara ExpositoInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.ORCID 0000-0002-8527-0573
Maria EspelosinGene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, Pamplona, Spain.
Clara CambriaDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, Milan, Italy.
Laura D'AndreaDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.
Gabriele ImperatoDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.
Pedram MoeiniDNA and RNA Medicine Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Africa ValesDNA and RNA Medicine Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.ORCID 0009-0000-4507-8117
Gloria Gonzalez-AseguinolazaDNA and RNA Medicine Division, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Nico MitroDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.ORCID 0000-0002-5000-3619
Flavia AntonucciDepartment of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, Milan, Italy.
Eduardo D MartínInstituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Elena MarcelloDepartment of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, Milan, Italy.
Mar Cuadrado-TejedorGene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, Pamplona, Spain mcuadrado@unav.es.ORCID 0000-0003-4260-9140
Ana Garcia-OstaGene Therapy for CNS Disorders Program, Center for Applied Medical Research (CIMA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, Pamplona, Spain agosta@unav.es.ORCID 0000-0001-6326-9064

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given its potential role in supporting cognitive resilience, PLA2G4E has emerged as a compelling therapeutic target in the context of Alzheimer's disease (AD). However, its physiological functions in the central nervous system remain largely unexplored. In this study, we demonstrate that Pla2g4e expression peaks during early postnatal brain development, coinciding with the rapid formation of synapses. Loss-of-function experiments in primary neuronal cultures revealed that Pla2g4e expression is essential for proper dendritic development and neuronal maturation. In constitutive Pla2g4e knockout mice, we observed significant disruptions in the developmental profiles of cortical synaptic plasticity markers, accompanied by impairments in memory-related behaviors. Notably, the adeno-associated virus-mediated overexpression of

Indexed as

CognitionGroup IV Phospholipases A2SynapsesAlzheimer DiseaseAnimalsBrainDendritesMaleMemory DisordersMiceMice, Inbred C57BLMice, KnockoutNeuronal PlasticityNeuronsGroup IV Phospholipases A2

Identifiers

PMID40634107
PMCPMC12241665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.